BRAF and melanoma: In the melanoma setting, BRAF inhibitors induce ATF4 translation through two independent signaling pathways: they trigger GCN2 kinase autophosphorylation that activates the canonical ISR (Nagasawa et al., 2017), but also can sustain mTOR- and eIF4B-driven ATF4 translation.